Evidence map›Paper›PMID 38344143›Full record

ArticleFrontiers in oncology2023

IMiD/CELMoD-induced growth suppression of adult T-cell leukemia/lymphoma cells

Yu Wang, Shunsuke Shimosaki, Emi Ikebe, Hidekatsu Iha, Jun-Ichi Yamamoto, Nichole Fife, Tomonaga Ichikawa, Mitsuo Hori, Masao Ogata, Yoshiyuki Tsukamoto and 9 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.2field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 8 institutions in 2 countries.

Yu Wang *Department of Microbiology, Faculty of Medicine, Oita University, Yufu, Japan.
Shunsuke Shimosaki *Division of Tumor and Cellular Biochemistry, Department of Medical Sciences, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.
Emi Ikebe *Department of Microbiology, Faculty of Medicine, Oita University, Yufu, Japan.
Hidekatsu IhaDepartment of Microbiology, Faculty of Medicine, Oita University, Yufu, Japan.
Jun-Ichi YamamotoDepartment of Nanoparticle Translational Research, Tokyo Medical University, Tokyo, Japan.
Nichole FifeDepartment of Microbiology, Faculty of Medicine, Oita University, Yufu, Japan.
Tomonaga IchikawaDivision of Tumor and Cellular Biochemistry, Department of Medical Sciences, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.
Mitsuo HoriDepartment of Hematology, Ibaraki Prefectural Central Hospital, Kasama, Japan.
Masao OgataDivision of Pathophysiology, The Research Center for GLOBAL and LOCAL Infectious Diseases (RCGLID), Oita University, Yufu, Japan.
Yoshiyuki TsukamotoDepartment of Molecular Pathology, Faculty of Medicine, Oita University, Yufu, Japan.
Naoki HijiyaDepartment of Molecular Pathology, Faculty of Medicine, Oita University, Yufu, Japan.
Masatsugu MoriyamaDepartment of Molecular Pathology, Faculty of Medicine, Oita University, Yufu, Japan.
Shotaro HagiwaraMito Center for Regional Medical Education, University of Tsukuba, Ibaraki, Japan.
Shuichi KusanoDivision of Biological Information Technology, Joint Research Center for Human Retrovirus Infection, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan.
Masumichi SaitoResearch Center for Biological Products in the Next Generation, National Institute of Infectious Diseases, Musashi-murayama, Japan.
Kamruddin AhmedBorneo Medical and Health Research Centre, Faculty of Medicine and Health Sciences, University of Malaysia Sabah, Kota Kinabalu, Malaysia.
Akira NishizonoDepartment of Microbiology, Faculty of Medicine, Oita University, Yufu, Japan.
Hiroshi HandaDepartment of Nanoparticle Translational Research, Tokyo Medical University, Tokyo, Japan.
Kazuhiro MorishitaDivision of Tumor and Cellular Biochemistry, Department of Medical Sciences, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.
Oita University · JPUniversity of Miyazaki · JPTokyo Medical University · JPUniversiti of Malaysia Sabah · MYIbaraki Prefectural Central Hospital · JPKagoshima University · JPNational Institute of Infectious Diseases · JPUniversity of Tsukuba · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Adult T-cell leukemia/lymphoma (ATL) is an aggressive T-cell neoplasia associated with human T-cell leukemia virus type 1 (HTLV-1) infection and has an extremely poor prognosis. Lenalidomide (LEN; a second-generation immunomodulatory drug [IMiD]) has been employed as an additional therapeutic option for ATL since 2017, but its mechanism of action has not been fully proven, and recent studies reported emerging concerns about the development of second primary malignancies in patients treated with long-term IMiD therapy. Our purpose in this study was to elucidate the IMiD-mediated anti-ATL mechanisms. Thirteen ATL-related cell lines were divided into LEN-sensitive or LEN-resistant groups.

Indexed as

adult T-cell lymphoma/leukemiacereblon modulator (CELMoD)CRBNHTLV-1IKZF2immunomodulatory drug (IMiDs)IRF4

Identifiers

PMID38344143
PMCPMC10853999
OpenAlexW4391256715

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.